Logo image of CYCN

CYCLERION THERAPEUTICS INC (CYCN) Stock Fundamental Analysis

NASDAQ:CYCN - Nasdaq - US23255M2044 - Common Stock - Currency: USD

2.64  -0.09 (-3.3%)

After market: 2.7 +0.06 (+2.27%)

Fundamental Rating

2

Overall CYCN gets a fundamental rating of 2 out of 10. We evaluated CYCN against 553 industry peers in the Biotechnology industry. While CYCN seems to be doing ok healthwise, there are quite some concerns on its profitability. CYCN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CYCN had negative earnings in the past year.
CYCN had a negative operating cash flow in the past year.
CYCN had negative earnings in each of the past 5 years.
CYCN had a negative operating cash flow in each of the past 5 years.
CYCN Yearly Net Income VS EBIT VS OCF VS FCFCYCN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -29.90%, CYCN is in the better half of the industry, outperforming 66.55% of the companies in the same industry.
CYCN's Return On Equity of -33.53% is fine compared to the rest of the industry. CYCN outperforms 74.68% of its industry peers.
Industry RankSector Rank
ROA -29.9%
ROE -33.53%
ROIC N/A
ROA(3y)-104.94%
ROA(5y)-93.87%
ROE(3y)-166.99%
ROE(5y)-147.78%
ROIC(3y)N/A
ROIC(5y)N/A
CYCN Yearly ROA, ROE, ROICCYCN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CYCN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYCN Yearly Profit, Operating, Gross MarginsCYCN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for CYCN has been increased compared to 1 year ago.
The number of shares outstanding for CYCN has been increased compared to 5 years ago.
CYCN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CYCN Yearly Shares OutstandingCYCN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
CYCN Yearly Total Debt VS Total AssetsCYCN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -33.84, we must say that CYCN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -33.84, CYCN is doing worse than 89.87% of the companies in the same industry.
CYCN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -33.84
ROIC/WACCN/A
WACCN/A
CYCN Yearly LT Debt VS Equity VS FCFCYCN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

2.3 Liquidity

A Current Ratio of 4.21 indicates that CYCN has no problem at all paying its short term obligations.
CYCN has a Current ratio (4.21) which is in line with its industry peers.
A Quick Ratio of 4.21 indicates that CYCN has no problem at all paying its short term obligations.
CYCN has a Quick ratio of 4.21. This is comparable to the rest of the industry: CYCN outperforms 49.01% of its industry peers.
Industry RankSector Rank
Current Ratio 4.21
Quick Ratio 4.21
CYCN Yearly Current Assets VS Current LiabilitesCYCN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 46.04% over the past year.
CYCN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -15.01% yearly.
EPS 1Y (TTM)46.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y-20.23%
Revenue growth 5Y-15.01%
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CYCN Yearly Revenue VS EstimatesCYCN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2024 1M 2M 3M 4M
CYCN Yearly EPS VS EstimatesCYCN Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CYCN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYCN Price Earnings VS Forward Price EarningsCYCN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYCN Per share dataCYCN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CYCN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYCLERION THERAPEUTICS INC

NASDAQ:CYCN (7/30/2025, 8:00:01 PM)

After market: 2.7 +0.06 (+2.27%)

2.64

-0.09 (-3.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05
Earnings (Next)08-05 2025-08-05
Inst Owners12.26%
Inst Owner Change0%
Ins Owners24.48%
Ins Owner Change13.34%
Market Cap8.47M
Analysts82.86
Price TargetN/A
Short Float %0.81%
Short Ratio0.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.07
P/FCF N/A
P/OCF N/A
P/B 0.97
P/tB 0.97
EV/EBITDA N/A
EPS(TTM)-1.16
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.07
FCFYN/A
OCF(TTM)-1.07
OCFYN/A
SpS0.65
BVpS2.74
TBVpS2.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.9%
ROE -33.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-104.94%
ROA(5y)-93.87%
ROE(3y)-166.99%
ROE(5y)-147.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.21
Quick Ratio 4.21
Altman-Z -33.84
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y-20.23%
Revenue growth 5Y-15.01%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y62.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y89.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y89.91%
OCF growth 3YN/A
OCF growth 5YN/A